Bharat Serums and Vaccines (BSV) in partnership with Indian Society of Assisted Reproduction (ISAR), Academy of Clinical Embryologists (ACE), Indian Fertility Society (IFS) and Institute of Medicine and Law, convened a two-day conclave in Delhi on November 19-20, 2022.
The conclave focused on consultative discussions on several topics covered under the Assisted Reproductive Technology Act, 2022 (the ART Act). One of the most significant outcomes of the conclave has been the creation of an email helpdesk: bsv.arthelpdesk@imlindia.com.
Any queries from centers of experts on the ART Act and Surrogacy Act emailed to this helpdesk will be answered by legal experts from the Institute of Medicine and Law, within 48 hours.
The conclave was the first such platform which had the participation of all the three leading bodies, namely ISAR, IFS and ACE, along with the expert consultants in the national board of ART Act, 2022. It witnessed several leading experts on infertility discuss the implications of the ART Act on IVF treatments as well as the clinical challenges around the ART Act, in addition to broader discussions on male infertility, immunotherapies and scientific and medical advances in IVF treatment.
Read more at – https://www.healthcareradius.in/events/two-day-conclave-to-discuss-art-act-2022-held
“This Act was the need of the hour, and we are delighted that it has finally been introduced. However, the ART Act has many legal facets to it that should be understood in terms of treatments being availed by patients. Through this consultative approach, we endeavor to bring greater awareness, adherence, and accountability to the ART Act,”